| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| 50g |
|
||
| 100g |
|
||
| Other Sizes |
| Targets |
6-Chloro-1,3,5-triazine-2,4-diamine (3397-62-4) does not have a defined pharmacological target as it is primarily a synthetic reagent and catalyst. However, it is functionally related to 1,3,5-triazine-2,4-diamine and 2-chloro-1,3,5-triazine. The compound has been identified by the US Environmental Protection Agency (EPA) as 2,4-diamino-6-chloro-s-triazine (DACT), which can cause developmental toxicity and female reproductive toxicity. This toxicological profile suggests potential interactions with endocrine or developmental regulatory pathways.
|
|---|---|
| ln Vitro |
Not applicable as 6-Chloro-1,3,5-triazine-2,4-diamine (3397-62-4) is a synthetic reagent without established pharmacological activity. However, the compound has been reported by the EPA to exhibit developmental toxicity and female reproductive toxicity, suggesting some biological activity in mammalian systems. Related s-triazine herbicides and metabolites are known to interfere with endocrine function and hormonal regulation. Detailed IC50 or EC50 values for specific biological targets are not available in the literature for this compound.
|
| ln Vivo |
Not applicable as 6-Chloro-1,3,5-triazine-2,4-diamine (3397-62-4) is a synthetic reagent without documented in vivo activity. However, EPA toxicological assessments indicate that this compound (as DACT) possesses the potential to cause developmental toxicity and female reproductive toxicity in animal models. Studies on structurally similar triazine compounds have demonstrated endocrine-disrupting effects including altered estrous cycling, reduced fertility, and developmental abnormalities in offspring following gestational exposure. Detailed animal model information is not publicly available for this specific compound.
|
| Enzyme Assay |
Not applicable as 6-Chloro-1,3,5-triazine-2,4-diamine (3397-62-4) is a synthetic reagent without reported receptor binding assays. For general binding studies applicable to triazine compounds, typical protocols involve radioligand binding assays using membrane preparations containing relevant receptors (e.g., estrogen receptor, androgen receptor). Binding reactions are incubated at room temperature or 4degC for 1-16 hours, followed by filtration through glass fiber filters or centrifugation to separate bound from free ligand. Nonspecific binding is determined using excess cold ligand.
|
| Cell Assay |
Not applicable as 6-Chloro-1,3,5-triazine-2,4-diamine (3397-62-4) is a synthetic reagent without reported cell-based activity. For general cell viability studies applicable to triazine compounds, standard protocols involve culturing mammalian cells (e.g., HepG2, CHO, or MCF-7 cells) in appropriate growth medium (DMEM or RPMI with 10% FBS, 1% penicillin/streptomycin) at 37degC in 5% CO2. Cells are seeded in 96-well plates, treated with test compound for 24-72 hours, and viability assessed using MTT, XTT, or CellTiter-Glo assays.
|
| Animal Protocol |
Not applicable as 6-Chloro-1,3,5-triazine-2,4-diamine (3397-62-4) is a synthetic reagent without documented in vivo animal protocols. For reproductive and developmental toxicity studies potentially applicable to this compound, standard OECD test guidelines (e.g., OECD 415 for one-generation reproduction study or OECD 414 for prenatal developmental toxicity study) are typically followed. Rodents (rats or mice) receive test compound via oral gavage at multiple dose levels during gestation or throughout mating. Endpoints include maternal toxicity, fertility indices, litter size, pup viability, and offspring malformations.
|
| ADME/Pharmacokinetics |
Not applicable as 6-Chloro-1,3,5-triazine-2,4-diamine (3397-62-4) is a synthetic reagent without documented pharmacokinetic studies. For structurally related triazine compounds, typical PK properties include: moderate oral absorption, extensive hepatic metabolism via cytochrome P450 enzymes (particularly CYP1A2 and CYP3A4), plasma protein binding varying between 30-70%, elimination half-life ranging from several hours to days depending on the specific compound, and excretion primarily in urine as metabolites. Detailed human PK data for this specific compound are not available.
|
| Toxicity/Toxicokinetics |
According to the US Environmental Protection Agency (EPA), 6-Chloro-1,3,5-triazine-2,4-diamine (as 2,4-diamino-6-chloro-s-triazine, DACT) can cause developmental toxicity and female reproductive toxicity. The compound is classified as potentially hazardous. Safety precautions include storage in a cool, dry place away from incompatible materials. It may cause skin and eye irritation upon contact. The oral LD50 in rats has not been reported. Users should refer to the Safety Data Sheet (SDS) for comprehensive safety information prior to handling.
|
| Additional Infomation |
6-Chloro-1,3,5-triazine-2,4-diamine (3397-62-4) has a molecular formula of C3H4ClN5 and molecular weight of 145.55 g/mol. Its IUPAC name is 6-chloro-1,3,5-triazine-2,4-diamine. Additional synonyms include 2-chloro-4,6-diamino-1,3,5-triazine, chloroammeline, and AtraMod. The compound is typically stored at room temperature in a dry, well-ventilated area with protection from light and moisture. Purity specifications typically exceed 95% by HPLC. The product is classified as a biochemical assay reagent and organic synthesis catalyst.
|
| Molecular Formula |
C3H4CLN5
|
|---|---|
| Molecular Weight |
145.55
|
| Exact Mass |
145.016
|
| CAS # |
3397-62-4
|
| Related CAS # |
6-Chloro-1,3,5-triazine-2,4-diamine-13C3; 1216850-33-7
|
| PubChem CID |
18831
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
9
|
| Complexity |
88.2
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1(=NC(=NC(=N1)Cl)N)N
|
| InChi Key |
FVFVNNKYKYZTJU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C3H4ClN5/c4-1-7-2(5)9-3(6)8-1/h(H4,5,6,7,8,9)
|
| Chemical Name |
6-chloro-1,3,5-triazine-2,4-diamine
|
| Synonyms |
2-Chloro-4,6-diamino-1,3,5-triazine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~40 mg/mL (~274.82 mM; with sonication (<60°C))
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.8705 mL | 34.3525 mL | 68.7049 mL | |
| 5 mM | 1.3741 mL | 6.8705 mL | 13.7410 mL | |
| 10 mM | 0.6870 mL | 3.4352 mL | 6.8705 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
